Immune checkpoint inhibitors have become an important treatment option in patients with metastatic lung cancer. The current podcast gives an overview on the current evidence of immune checkpoint inhibitors in patients with non-small cell lung cancer. Based on the phase III data, patients with PDL1 expression >50% are candidates for first-line pembrolizumab if there are no contraindications. Currently, PDL1 expression as assessed by immunohistochemistry is the most validated biomarker although other biomarkers including mutational load, neoantigen presence or tumour infiltrating lymphocytes are currently under investigation. Importantly, the side effect profile of immune checkpoint inhibitors does not differ in patients with lung cancer. Studies are currently investigating the value of immune checkpoint inhibitors for patients with small cell lung cancer. Several currently ongoing studies are investigating the combination of chemotherapy/radiotherapy and immune checkpoint inhibitors in patients with lung cancer.
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